Zobrazeno 1 - 10
of 92
pro vyhledávání: '"C E M, Griffiths"'
Autor:
A. Y. Finlay, J. N. Barker, A. D. Burden, C. E. M. Griffiths, B. Kirby, M. L. Goodman, C. Neill, R. B. Warren
Publikováno v:
JEADV Clinical Practice, Vol 1, Iss 3, Pp 207-218 (2022)
Abstract Background The Family Dermatology Life Quality Index (FDLQI) was developed to meet a need for a dermatology‐specific family member/partner quality‐of‐life (QoL) measure. This paper focuses on the analysis and interpretation of FDLQI da
Externí odkaz:
https://doaj.org/article/885e1faf40d14c64a60a1ef0cf072503
Autor:
Niall J Davison, G Vander Stichele, Katherine Payne, G Dalal, Catherine H. Smith, Caroline Vass, C E M Griffiths, Stuart Wright
Publikováno v:
Dalal, G, Wright, S, Vass, C, Davison, N, Vander Stichele, G, Smith, C H, Griffiths, C E M & Payne, K 2021, ' Patient preferences for stratified medicine in psoriasis: a discrete choice experiment ', British Journal of Dermatology, vol. 185, no. 5, pp. 978-987 . https://doi.org/10.1111/bjd.20482
Background: New technologies have enabled the potential for stratified medicine in psoriasis. It is important to understand patients’ preferences to enable the informed introduction of stratified medicine, which is likely to involve a number of ind
Autor:
Joseph F. Merola, Alice B. Gottlieb, C E M Griffiths, Pascale Pellet, Luminita Pricop, Weibin Bao, I.B. McInnes, P. Nash, Frank Behrens, Kristian Reich
Publikováno v:
British Journal of Dermatology. 185:1124-1134
BACKGROUND Secukinumab [an interleukin (IL)-17A inhibitor] has demonstrated significantly higher efficacy vs. etanercept (a tumour necrosis factor inhibitor) and ustekinumab (an IL-12/23 inhibitor) in patients with moderate-to-severe plaque psoriasis
Autor:
P. M. Machado, M. Schaefer, S. Mahil, N. Dand, M. Gianfrancesco, S. Lawson-Tovey, Z. Yiu, M. Yates, K. Hyrich, L. Gossec, L. Carmona, E. Mateus, D. Wiek, S. Bhana, M. Gore-Massy, R. Grainger, J. Hausmann, P. Sufka, E. Sirotich, Z. Wallace, T. Olofsson, C. Lomater, N. Romeo, D. Wendling, T. Pham, C. Miceli Richard, B. Fautrel, L. Silva, H. Santos, F. R. Martins, R. Hasseli, A. Pfeil, A. Regierer, C. Isnardi, E. Soriano, R. Quintana, F. Omura, F. Machado Ribeiro, M. Pinheiro, W. Bautista-Molano, D. Alpizar-Rodriguez, C. Saad, M. Dubreuil, N. Haroon, L. S. Gensler, J. Dau, L. Jacobsohn, J. Liew, A. Strangfeld, J. Barker, C. E. M. Griffiths, P. Robinson, J. Yazdany, C. Smith
Publikováno v:
Annals of the Rheumatic Diseases. 81:163-164
BackgroundSome factors associated with severe COVID-19 outcomes have been identified in patients with psoriasis (PsO) and inflammatory/autoimmune rheumatic diseases, namely older age, male sex, comorbidity burden, higher disease activity, and certain
Autor:
A, Blauvelt, C, Leonardi, B, Elewski, J J, Crowley, L C, Guenther, M, Gooderham, R G, Langley, R, Vender, A, Pinter, C E M, Griffiths, Y, Tada, H, Elmaraghy, R G, Lima, G, Gallo, L, Renda, R, Burge, S Y, Park, B, Zhu, K, Papp
Publikováno v:
The British journal of dermatology. 184(6)
Significantly more patients with moderate-to-severe plaque psoriasis treated with the interleukin (IL)-17A inhibitor ixekizumab vs. the IL-23p19 inhibitor guselkumab in the IXORA-R head-to-head trial achieved 100% improvement in Psoriasis Area and Se
Autor:
Kathleen McElhone, N. J. Reynolds, S. Williams, Z.K. Jabbar‐Lopez, C. M. Owen, C.E. Kleyn, Z.Z.N. Yiu, Catherine H. Smith, Richard B. Warren, Nina Wilson, Darren M. Ashcroft, C. E. M. Griffiths, K.J. Mason
Publikováno v:
British Journal of Dermatology. 181
Publikováno v:
British Journal of Dermatology. 180
Publikováno v:
British Journal of Dermatology. 180
Publikováno v:
British Journal of Dermatology. 175:205-214
Autor:
Zenas Z N Yiu, Mark Lunt, Sinead Langan, Rosa Parisi, Richard B. Warren, Darren M. Ashcroft, C. E. M. Griffiths
Publikováno v:
Journal of Investigative Dermatology. 140:S52